Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGP2304 in Essential Hypertension
NCT06174766Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HGP2304-1 in essential hypertension, sponsored by Hanmi Pharmaceutical. Started May 2024; status: completed.
02
Drugs
HGP2304-1
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06174766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06174766.